Navigation Links
Combination therapy rids common infection from implanted medical devices
Date:9/8/2011

Researchers at the University of Toronto have developed a therapy for a potentially deadly type of infection common in catheters, artificial joints and other "in-dwelling" medical devices. Their findings appear in the Open Access Journal PLoS Pathogens on September 8th.

The therapy targets fungal infections, which are hard to treat in such devices because they are composed of biofilmscomplex groupings of cells that attach to surfaces. Biofilms, in turn, are coated in a gooey matrix that resists drugs.

Patients often undergo surgical removal of the infected catheter or other device in an attempt to clear the disease and prevent a system-wide dispersal of infecting cells.

In this study, researchers showed that inhibiting the function of a protein called Hsp90 abolishes drug resistance in the two main fungal pathogens of humans, Candida albicans and Aspergillus fumigatus. "It takes classic antifungals, which were not effective against biofilms, and makes them very effective," said Prof. Leah Cowen, principal investigator on the study who holds the Canada Research Chair in Microbial Genomics and Infectious Disease at U of T's Department of Molecular Genetics.

In an animal model of a central venous catheter infected with deadly fungus, the researchers were able to completely clear the infection by inhibiting Hsp90 and applying antifungals.

Fungal pathogens are a major clinical problem. Candida albicans is the third-leading cause of intravascular catheter-related infections, and is fatal in about 30% of infections associated with devices. And the number of acquired fungal bloodstream infections has increased by more than 200% over the last two decades, partly because successful treatments for previously fatal diseases like cancer and AIDS have left many patients immune-compromised and susceptible to infection.

With more than 10 million patients per year now receiving catheters, artificial joints and other devices, there is a pressing need for a better understanding of biofilms and their role in drug resistance of fungal pathogens.


'/>"/>
Contact: Jim Oldfield
jim.oldfield@utoronto.ca
416-946-8423
Public Library of Science
Source:Eurekalert

Related medicine news :

1. WHI data confirm short-term heart disease risks of combination menopausal hormone therapy
2. Combination therapy more effective for enlarged prostate
3. Combination Treatment May Help Depressed Alcoholics
4. Researchers find new chemotherapy combination shows promise in endometrial cancer
5. Leeza Gibbons and ZERONA Equals a Winning Combination
6. Combination antibiotics effective against chlamydia-induced arthritis
7. Hair Loss Doctor Overcomes Odds To Produce First Ever Combination Topical Hair Growth Formula
8. Combination therapy targets stubborn leukemia stem cells
9. Combination treatment regimen not effective against advanced melanoma
10. New combination effective against pancreatic cancer
11. Noninvasive combination technique may reduce number of breast biopsies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... ... not your typical author. She went from working as a movie extra on Bill Murray’s ... she isn’t swimming as a performing mermaid. , Her book isn’t typical either. In Carothers’ ... comedic look at the dysfunctions of God’s family, before Lucifer was sent to hell. ...
(Date:2/27/2017)... ... February 27, 2017 , ... Texas based retail ... addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds 150,000. , ... had 800 customers and 2,250 RCEs at the time of acquisition. In the ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination of Kim ... over nerve agents and the deadly use of chemical weapons. Many questions exist about ... even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan Neurosurgical ...
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is ... Pay-For-Performance B2B Marketing. B2B Sellers will now only pay for B.A.N.T. quality sales leads ... founder of IndustryArchive.Org, said, “Given the new reality that B2B buyers are controlling the ...
(Date:2/25/2017)... ... ... FCPX users now have the ability to sharpen a desired color range ... have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, vertical sharpening, and ... can visually see the color range effected with ease all within Final Cut ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 2017  Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a ... diagnostic tests and pathology services, announced today the acceptance ... United States and Canadian Academy ... in San Antonio, Texas . ... from the Company,s extensive experience in molecular thyroid testing, ...
(Date:2/27/2017)... 27, 2017  International Biophysics Corporation, a global medical device ... announced a 34% revenue growth in 2016 when compared to ... sales.  This growth was fueled by its AffloVest® sales in ... the expansion of its global sales of surgical product lines. ... "As we enter our 25 th year in delivering ...
(Date:2/27/2017)... 2017   Vitasome ® Labs , Inc. ... its groundbreaking new liposome technology. Whereas vitamins lose on ... digestion per Physician,s Desk Reference , Vitasome , ... nutritional waste and are scientifically formulated to: ... Improve bioavailability with a vastly higher absorption ...
Breaking Medicine Technology: